122 related articles for article (PubMed ID: 30914386)
1. Computational screening of potential drug targets for pathogens causing bacterial pneumonia.
Nayak S; Pradhan D; Singh H; Reddy MS
Microb Pathog; 2019 May; 130():271-282. PubMed ID: 30914386
[TBL] [Abstract][Full Text] [Related]
2. Subtractive genome analysis for in silico identification and characterization of novel drug targets in Streptococcus pneumonia strain JJA.
Wadood A; Jamal A; Riaz M; Khan A; Uddin R; Jelani M; Azam SS
Microb Pathog; 2018 Feb; 115():194-198. PubMed ID: 29277475
[TBL] [Abstract][Full Text] [Related]
3. Core Proteomic Analysis of Unique Metabolic Pathways of Salmonella enterica for the Identification of Potential Drug Targets.
Uddin R; Sufian M
PLoS One; 2016; 11(1):e0146796. PubMed ID: 26799565
[TBL] [Abstract][Full Text] [Related]
4. Unraveling novel broad-spectrum antibacterial targets in food and waterborne pathogens using comparative genomics and protein interaction network analysis.
Jadhav A; Shanmugham B; Rajendiran A; Pan A
Infect Genet Evol; 2014 Oct; 27():300-8. PubMed ID: 25128740
[TBL] [Abstract][Full Text] [Related]
5. TiD: Standalone software for mining putative drug targets from bacterial proteome.
Gupta R; Pradhan D; Jain AK; Rai CS
Genomics; 2017 Jan; 109(1):51-57. PubMed ID: 27856224
[TBL] [Abstract][Full Text] [Related]
6. Comparative genomic analysis of Rickettsia rickettsii for identification of drug and vaccine targets: tolC as a proposed candidate for case study.
Maurya PK; Singh S; Mani A
Acta Trop; 2018 Jun; 182():100-110. PubMed ID: 29474831
[TBL] [Abstract][Full Text] [Related]
7. Identification of putative non-host essential genes and novel drug targets against Acinetobacter baumannii by in silico comparative genome analysis.
Uddin R; Masood F; Azam SS; Wadood A
Microb Pathog; 2019 Mar; 128():28-35. PubMed ID: 30550846
[TBL] [Abstract][Full Text] [Related]
8. Microbial pathogens of adult community-acquired pneumonia in Southern Estonia.
Leesik H; Ani U; Juhani A; Altraja A
Medicina (Kaunas); 2006; 42(5):384-94. PubMed ID: 16778466
[TBL] [Abstract][Full Text] [Related]
9. Novel Drug Targets for Food-Borne Pathogen Campylobacter jejuni: An Integrated Subtractive Genomics and Comparative Metabolic Pathway Study.
Mehla K; Ramana J
OMICS; 2015 Jul; 19(7):393-406. PubMed ID: 26061459
[TBL] [Abstract][Full Text] [Related]
10. Identification of druggable targets for Acinetobacter baumannii via subtractive genomics and plausible inhibitors for MurA and MurB.
Kaur N; Khokhar M; Jain V; Bharatam PV; Sandhir R; Tewari R
Appl Biochem Biotechnol; 2013 Sep; 171(2):417-36. PubMed ID: 23846799
[TBL] [Abstract][Full Text] [Related]
11. Proteome mining for the identification and in-silico characterization of putative drug targets of multi-drug resistant Clostridium difficile strain 630.
Lohani M; Dhasmana A; Haque S; Wahid M; Jawed A; Dar SA; Mandal RK; Areeshi MY; Khan S
J Microbiol Methods; 2017 May; 136():6-10. PubMed ID: 28235560
[TBL] [Abstract][Full Text] [Related]
12. Identification of novel non-homologous drug targets against Acinetobacter baumannii using subtractive genomics and comparative metabolic pathway analysis.
Kaur H; Kalia M; Taneja N
Microb Pathog; 2021 Mar; 152():104608. PubMed ID: 33166618
[TBL] [Abstract][Full Text] [Related]
13. Comparative Metabolic Pathways Analysis and Subtractive Genomics Profiling to Prioritize Potential Drug Targets Against
Khan K; Jalal K; Khan A; Al-Harrasi A; Uddin R
Front Microbiol; 2021; 12():796363. PubMed ID: 35222301
[No Abstract] [Full Text] [Related]
14. Macrolones Are a Novel Class of Macrolide Antibiotics Active against Key Resistant Respiratory Pathogens In Vitro and In Vivo.
Čipčić Paljetak H; Verbanac D; Padovan J; Dominis-Kramarić M; Kelnerić Ž; Perić M; Banjanac M; Ergović G; Simon N; Broskey J; Holmes DJ; Eraković Haber V
Antimicrob Agents Chemother; 2016 Sep; 60(9):5337-48. PubMed ID: 27353268
[TBL] [Abstract][Full Text] [Related]
15. Metabolic pathway analysis approach: identification of novel therapeutic target against methicillin resistant Staphylococcus aureus.
Uddin R; Saeed K; Khan W; Azam SS; Wadood A
Gene; 2015 Feb; 556(2):213-26. PubMed ID: 25436466
[TBL] [Abstract][Full Text] [Related]
16. In vivo pharmacodynamic efficacy of gatifloxacin against Streptococcus pneumoniae in an experimental model of pneumonia: impact of the low levels of fluoroquinolone resistance on the enrichment of resistant mutants.
Croisier D; Etienne M; Piroth L; Bergoin E; Lequeu C; Portier H; Chavanet P
J Antimicrob Chemother; 2004 Sep; 54(3):640-7. PubMed ID: 15317743
[TBL] [Abstract][Full Text] [Related]
17. Antimicrobial susceptibility of pneumococcal isolates causing bacteraemic pneumococcal pneumonia: analysis using current breakpoints and fluoroquinolone pharmacodynamics.
Feldman C; Brink AJ; von Gottberg A; Wolter N; de Gouveia L; Perovic O; Klugman KP
Int J Antimicrob Agents; 2010 Jul; 36(1):95-7. PubMed ID: 20378315
[No Abstract] [Full Text] [Related]
18. Target identification in Fusobacterium nucleatum by subtractive genomics approach and enrichment analysis of host-pathogen protein-protein interactions.
Kumar A; Thotakura PL; Tiwary BK; Krishna R
BMC Microbiol; 2016 May; 16():84. PubMed ID: 27176600
[TBL] [Abstract][Full Text] [Related]
19. Risk Factors for Community-Onset Pneumonia Caused by Levofloxacin-Nonsusceptible Streptococcus pneumoniae.
Seok H; Kang CI; Huh K; Cho SY; Ha YE; Chung DR; Peck KR
Microb Drug Resist; 2018 Nov; 24(9):1412-1416. PubMed ID: 29565225
[TBL] [Abstract][Full Text] [Related]
20. An Approach for Identification of Novel Drug Targets in Streptococcus pyogenes SF370 Through Pathway Analysis.
Singh S; Singh DB; Singh A; Gautam B; Ram G; Dwivedi S; Ramteke PW
Interdiscip Sci; 2016 Dec; 8(4):388-394. PubMed ID: 26750924
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
